The evaluation of inhibitive effectiveness of the tumour necrosis factor-α converting enzyme selective inhibitors by HPLC

J Enzyme Inhib Med Chem. 2011 Apr;26(2):181-7. doi: 10.3109/14756366.2010.487485.

Abstract

A novel high-performance liquid chromatography (HPLC) method based on the internal standard method was established for assaying the tumour necrosis factor-α converting enzyme (TACE) activity and matrix metalloprotease-9 (MMP-9) activity, and was used to evaluate the inhibitive effectiveness of inhibitors to TACE and MMP-9. In the assay method for TACE and MMP-9, peptides labelled with the ultraviolet group-Dpa were used as substrates. Alanine-Dpa was synthesised and was used as the internal standard for quantitative analysis. After the peptide substrates were hydrolysed by TACE (MMP-9) for 15 min (25 min) at 37 °C, the amount of remaining substrates were determined by reversed-phased HPLC with UV detection at 353 nm. The relative peak area of the substrate was linearly dependent on the substrate concentration. This method was then applied to determine the 50% inhibitory concentration (IC₅₀) of GM6001 and inhibitor A for both TACE and MMP-9.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins / antagonists & inhibitors*
  • ADAM Proteins / chemistry
  • ADAM17 Protein
  • Chemistry Techniques, Analytical
  • Chromatography, High Pressure Liquid
  • Enzyme Activation / drug effects*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Inhibitory Concentration 50
  • Matrix Metalloproteinase 9 / chemistry
  • Matrix Metalloproteinase Inhibitors
  • Molecular Structure
  • Substrate Specificity

Substances

  • Enzyme Inhibitors
  • Matrix Metalloproteinase Inhibitors
  • ADAM Proteins
  • Matrix Metalloproteinase 9
  • ADAM17 Protein
  • ADAM17 protein, human